Report Description Table of Contents What Is the Acute Coronary Syndrome Market Size and What Is Shaping Its Clinical Landscape? – (Updated On: 26-Aug-2026) The Global Acute Coronary Syndrome Market was valued at USD 10.25 billion in 2025 and is projected to reach USD 16.03 billion by 2032, expanding at a CAGR of 6.6% during 2026–2032, according to Strategic Market Research. Acute coronary syndrome is a medical emergency caused by a sudden reduction in blood flow to the heart. It includes STEMI, NSTEMI, and unstable angina. The condition requires rapid diagnosis and treatment across emergency departments, hospital laboratories, catheterization laboratories, cardiac surgery units, and follow-up cardiovascular care. Major antiplatelet therapies include Plavix (clopidogrel), Brilinta (ticagrelor), and Effient (prasugrel). Anticoagulants such as heparin and enoxaparin are also widely used to reduce clot formation. Additional treatment commonly involves aspirin, beta-blockers, and nitroglycerin. Together these therapies support immediate patient stabilization and long-term prevention of recurrent cardiac events. Acute Coronary Syndrome (ACS) represents a major global cardiovascular burden, with more than 7 million people diagnosed worldwide each year. In the United States, ACS contributes to over 1 million hospitalizations annually, while CDC data indicate approximately 805,000 heart attacks occur each year. Around 200,000 of these heart attacks occur in people who have previously experienced one, highlighting the substantial risk of recurrent cardiovascular events. Key Acute Coronary Syndrome Market Takeaways Across Syndrome Type, Treatment, End User and Geography By Syndrome Type NSTEMI: Accounted for 49.0% of the market or USD 5.023 billion in 2025 and is projected to expand at a CAGR of 6.9%, supported by its large clinical case load and improved detection with high-sensitivity troponin assays. STEMI: Represented 34.0% or USD 3.485 billion in 2025 and is projected to grow at a CAGR of 6.4%, with rapid PCI, stenting and reperfusion driving high treatment intensity. Unstable Angina: Held 17.0% or USD 1.743 billion in 2025 and is expected to grow at a CAGR of 5.7%, while high-sensitivity troponin testing continues to reclassify some historical unstable-angina presentations as NSTEMI. By Treatment Modality Medications: Led with 48.0% of the market or USD 4.920 billion in 2025 and a CAGR of 6.1%, covering antiplatelet, anticoagulant, lipid-lowering and other secondary-prevention therapies. Percutaneous Coronary Intervention: Accounted for 39.0% or USD 3.998 billion in 2025 and is projected to expand at a CAGR of 7.4%, supported by complex PCI, drug-eluting stents and greater intravascular-imaging use. Coronary Artery Bypass Grafting: Represented 13.0% or USD 1.333 billion in 2025 and is expected to grow at a CAGR of 5.8%, retaining an important role in selected patients with complex multivessel or left-main coronary disease. By End User Hospitals: Accounted for 66.0% of the market or USD 6.765 billion in 2025 and are projected to grow at a CAGR of 6.3%, reflecting their central role in emergency diagnosis, intensive monitoring and revascularization. Cardiac Centers: Represented 24.0% or USD 2.460 billion in 2025 and are projected to expand at a CAGR of 7.1%, supported by complex PCI, cardiac surgery and specialized coronary imaging. Ambulatory Surgical Centers: Held 10.0% or USD 1.025 billion in 2025 and are expected to grow at a CAGR of 7.4%, mainly through selected lower-risk cardiovascular procedures and follow-up care rather than the index emergency ACS episode. By Geography North America: Led with 39.0% or USD 3.998 billion in 2025 and is projected to grow at a CAGR of 5.8%, supported by extensive catheterization infrastructure, advanced diagnostics and established reimbursement. Europe: Accounted for 26.0% or USD 2.665 billion in 2025 and is expected to grow at a CAGR of 6.2%, supported by mature PCI networks and continued diagnostic innovation. Asia-Pacific: Represented 25.0% or USD 2.563 billion in 2025 and is projected to expand at the fastest CAGR of 8.2%, supported by expanding coronary intervention capacity and broader access to advanced devices. Latin America: Accounted for 6.0% or USD 0.615 billion in 2025 and is projected to grow at a CAGR of 6.9%, with development concentrated around emergency cardiac networks and catheterization capacity. Middle East & Africa: Represented 4.0% or USD 0.410 billion in 2025 and is expected to grow at a CAGR of 7.3%, reflecting expanding tertiary cardiac services alongside continued access differences across countries. Acute Coronary Syndrome Market by Syndrome Type: NSTEMI Leads as Diagnostic Classification Becomes More Precise NSTEMI accounted for 49.0% of the Acute Coronary Syndrome Market in 2025, representing approximately USD 5.023 billion, and is projected to expand at a CAGR of 6.9% during 2026–2032. As one of the three major clinical presentations of ACS, NSTEMI occurs when a partial blockage of a coronary artery reduces blood flow and causes localized heart muscle damage without complete vessel occlusion. ST-segment elevation myocardial infarction (STEMI) represented 34.0% of the Acute Coronary Syndrome Market in 2025, equivalent to approximately USD 3.485 billion, and is projected to grow at a CAGR of 6.4%. STEMI is the most severe form of acute coronary syndrome, typically resulting from a complete blockage of a coronary artery that sharply restricts blood flow to the heart muscle. Because it requires immediate emergency intervention to restore coronary blood flow and limit heart damage, STEMI accounts for substantial use of emergency diagnostics, antiplatelet and anticoagulant therapies, catheterization procedures, and percutaneous coronary intervention. Unstable angina accounted for 17.0% of the Acute Coronary Syndrome Market in 2025, corresponding to approximately USD 1.743 billion, and is expected to expand at a CAGR of 5.7%. As a major non-infarct form of acute coronary syndrome, unstable angina occurs when blood flow to the heart muscle is suddenly reduced, causing cardiac ischemia without the permanent myocardial tissue damage seen in a heart attack. Acute Coronary Syndrome Market by Treatment: Medications Lead While PCI Records Faster Expansion Medications accounted for 48.0% of the Acute Coronary Syndrome Market in 2025, representing approximately USD 4.920 billion, and are projected to expand at a CAGR of 6.1%. Their leading share reflects the critical role of drug therapy in preventing and breaking down blood clots, restoring coronary blood flow, relieving chest pain, and limiting permanent damage to the heart muscle. Percutaneous coronary intervention accounted for 39.0% of the Acute Coronary Syndrome Market in 2025, valued at approximately USD 3.998 billion, and is projected to expand at a CAGR of 7.4%. PCI is the primary catheter-based procedure used to rapidly reopen narrowed or blocked coronary arteries and restore blood flow to the heart during acute coronary syndrome, particularly in patients with myocardial infarction. Coronary artery bypass grafting (CABG) represented 13.0% of the Acute Coronary Syndrome Market in 2025, equivalent to approximately USD 1.333 billion, and is projected to expand at a CAGR of 5.8%. CABG remains an important surgical revascularization option for ACS patients when percutaneous coronary intervention (PCI) is unsuitable, cannot provide complete revascularization, or has failed. Acute Coronary Syndrome Market by End User: Hospitals Retain the Core Emergency and Interventional Role Hospitals accounted for 66.0% of the Acute Coronary Syndrome Market in 2025, representing approximately USD 6.765 billion, and are projected to grow at a CAGR of 6.3%. Their leading position reflects their critical role in providing rapid diagnosis, emergency stabilization, and timely reperfusion treatment to restore coronary blood flow during an acute coronary syndrome (ACS) event. Cardiac centers represented 24.0% of the Acute Coronary Syndrome Market in 2025, valued at approximately USD 2.460 billion, and are projected to expand at a CAGR of 7.1%. These centers play an important role in diagnosing, risk-stratifying, and managing ACS through cardiac biomarker testing, cardiovascular imaging, continuous monitoring, and specialist-led assessment. Ambulatory surgical centers accounted for 10.0% of the Acute Coronary Syndrome Market in 2025, corresponding to approximately USD 1.025 billion, and are expected to grow at a CAGR of 7.4%. However, ASCs generally do not manage active ACS cases, as heart attacks and unstable angina require immediate hospital-based emergency care, continuous cardiac monitoring, and access to intensive or interventional services. Their market role is therefore concentrated in selected elective and follow-up cardiovascular procedures related to patients with coronary artery disease, rather than emergency ACS treatment Acute Coronary Syndrome Market Regional Analysis Highlights Mature U.S. Infrastructure and Faster Asia-Pacific Expansion North America accounted for 39.0% of the Acute Coronary Syndrome Market in 2025, representing approximately USD 3.998 billion, and is projected to grow at a CAGR of 5.8%. The region leads in the adoption of advanced diagnostic protocols, specialized cardiac care networks, and precision treatment approaches for ACS. Hospitals widely use high-sensitivity cardiac troponin testing for rapid diagnosis and risk stratification, while established STEMI networks and chest pain centers help accelerate emergency treatment. North America also has high utilization of primary percutaneous coronary intervention (PCI) and intracoronary imaging for patients requiring revascularization. Treatment practices are strongly guided by recommendations from organizations such as the American Heart Association, including the use of dual antiplatelet therapy and complete revascularization when clinically appropriate. These established diagnostic, interventional, and treatment pathways support the region’s leading market position. Europe accounted for 26.0% of the Acute Coronary Syndrome Market in 2025, valued at USD 2.665 billion, and is projected to grow at a 6.2% CAGR. Market growth is supported by widespread use of guideline-based diagnosis, antiplatelet therapy, revascularization, and secondary prevention across major European healthcare systems. The regional disease burden remains substantial. France records roughly 80,000–100,000 hospital stays each year related to acute coronary syndromes, while Spain sees around 110,000 new cases annually. These volumes sustain demand for emergency cardiac care, interventional procedures, pharmaceuticals, and long-term cardiovascular management, although treatment consistency and access still vary across countries. Asia-Pacific accounted for 25.0% of the Acute Coronary Syndrome Market in 2025, valued at approximately USD 2.563 billion, and is projected to grow at a 8.2% CAGR during 2026–2032. The region’s large population and high cardiovascular disease burden create substantial demand for ACS diagnosis, emergency treatment, and long-term cardiac care. Growth is also being supported by expanding hospital capacity, wider use of interventional cardiology, and improving access to cardiovascular medicines. However, treatment patterns remain uneven because access to catheterization labs, angioplasty, advanced diagnostics, and specialist care differs significantly across countries and between major cities and rural areas. This gap creates both a healthcare challenge and a major opportunity for market expansion. Latin America accounted for 6.0% of the Acute Coronary Syndrome (ACS) Market in 2025, representing approximately USD 0.615 billion, and is projected to grow at a CAGR of 6.9%. Market development is shaped by the region’s gradual adoption of evidence-based ACS guidelines and treatment protocols, alongside persistent differences in healthcare infrastructure and access to timely cardiac care. Middle East & Africa represented 4.0% of the market, valued at USD 0.410 billion in 2025, and is expected to expand at a CAGR of 7.3%. High-capability tertiary hospitals in Gulf markets support advanced PCI and coronary imaging, while other parts of the region remain more dependent on essential antithrombotic therapy, thrombolysis and referral networks. Acute Coronary Syndrome Market Competitive Landscape Centers on Antiplatelet Therapy, Coronary Intervention and High-Sensitivity Diagnostics Competition is distributed across pharmaceuticals, coronary devices and diagnostics rather than dominated by a single product category. Companies compete through antiplatelet positioning, stent deliverability, lesion coverage, suitability for complex PCI, diagnostic sensitivity, installed laboratory platforms and integration with post-ACS cardiovascular prevention. Generic competition is pressuring older branded medicines, while procedural innovation and high-sensitivity testing provide stronger differentiation. AstraZeneca AstraZeneca participates through Brilinta/Brilique (ticagrelor), an oral P2Y12 platelet inhibitor used in ACS and prior MI. The FDA-approved product reduces platelet activation and clot formation and remains incorporated into guideline-directed ACS treatment. Its commercial profile is increasingly affected by generic ticagrelor entry in the United States and Europe, shifting competition toward price while preserving the drug class's clinical relevance. Abbott Abbott's coronary portfolio is led by the XIENCE family of everolimus-eluting stents. XIENCE Skypoint has FDA PMA approval and includes configurations for larger vessels and longer lesions. Its March 2026 introduction in India expanded Abbott's current-generation DES portfolio into another major interventional cardiology market, with positioning around complex PCI and broader vessel sizing. Medtronic Medtronic competes through Resolute Onyx and Onyx Frontier zotarolimus-eluting coronary stents. FDA PMA labeling includes patients with symptomatic ischemic heart disease and covers populations such as patients with diabetes or high bleeding risk, as well as selected chronic total occlusion and bifurcation lesions. The platform is therefore positioned around both routine and technically complex PCI. Boston Scientific Boston Scientific participates through SYNERGY coronary stents, coronary imaging and lesion-preparation technologies, along with the AGENT drug-coated balloon. FDA approved AGENT in 2024 for coronary in-stent restenosis, providing a treatment option that delivers an antiproliferative drug without implanting another permanent metal stent layer. This gives the company exposure to recurrent coronary intervention as well as primary PCI technologies. Roche Roche competes in the diagnostic portion of the pathway through its Elecsys high-sensitivity troponin portfolio. Elecsys Troponin T hs Gen 6 received CE marking in 2025 and was evaluated in the TSIX program. PERFORM-TSIX enrolled 5,631 patients across 50 sites, providing evidence for rapid rule-in and rule-out workflows in emergency departments. The commercial value is tied to faster triage and recurring assay utilization across the cobas installed base. Siemens Healthineers Siemens Healthineers participates through high-sensitivity cardiac troponin assays used on major laboratory platforms including Atellica systems. Its position is supported by hospitals that already use Siemens laboratory infrastructure, allowing ACS testing to contribute recurring reagent revenue while supporting serial troponin measurements and rapid emergency-department decision-making. Amgen Amgen participates in the longer post-ACS treatment pathway through Repatha (evolocumab), a PCSK9 inhibitor used to lower LDL cholesterol and reduce cardiovascular risk in appropriate patients. The 2025 ACS guideline includes evolocumab among non-statin options for patients whose LDL-C remains above recommended thresholds despite maximally tolerated statin therapy. This positions Amgen primarily in recurrent-event prevention rather than management of the acute coronary occlusion itself. Acute Coronary Syndrome Market Outlook Emphasizes Complex PCI, Faster Diagnosis and Recurrent-Event Prevention The Acute Coronary Syndrome Market is becoming less dependent on simple growth in the number of acute cardiac events and more dependent on the intensity of care provided during and after each episode. More sensitive troponin testing is altering the diagnosed case mix, intravascular imaging is becoming more important in complex PCI, and secondary-prevention strategies extend commercial involvement beyond hospital discharge. PCI is positioned to outpace the overall market as complex anatomy, multivessel revascularization and image-guided intervention increase technology utilization per procedure. At the same time, high-sensitivity diagnostics from companies such as Roche and Siemens Healthineers strengthen the diagnostic portion of the market by supporting faster rule-in and rule-out pathways. Acute Coronary Syndrome Market Report Coverage Table Report Attribute Details Forecast Period 2026–2032 Market Size Value in 2025 USD 10.25 Billion Revenue Forecast in 2032 USD 16.03 Billion Overall Growth Rate CAGR of 6.6% (2026–2032) Base Year for Estimation 2025 Historical Data 2019–2024 Unit USD Billion, CAGR (2026–2032) Segmentation By Syndrome Type, By Treatment Modality, By End User, and By Geography By Syndrome Type NSTEMI, STEMI, Unstable Angina By Treatment Modality Medications, Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting By End User Hospitals, Cardiac Centers, Ambulatory Surgical Centers By Geography North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, Netherlands, Sweden, Norway, China, Japan, India, South Korea, Australia, New Zealand, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa, and Other Countries Market Drivers High global cardiovascular burden, wider use of high-sensitivity troponin testing, expanding emergency PCI capacity, increasing adoption of drug-eluting stents and coronary imaging, guideline-directed antiplatelet therapy, and stronger post-ACS recurrent-event prevention Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the latest innovations transforming the market? A1. High-sensitivity troponin testing, intravascular imaging, newer drug-eluting stents and drug-coated balloons are changing the care pathway. These technologies support faster diagnosis and more precise treatment of complex coronary lesions while expanding the value generated during each acute episode. Q2. Which region currently leads the market and why? A2. North America leads because of its established STEMI networks, extensive catheterization-laboratory infrastructure and broad use of high-sensitivity cardiac biomarkers. High utilization of PCI and advanced coronary imaging also supports higher treatment intensity across major hospital systems. Q3. How is technology advancement influencing adoption in the industry? A3. Better diagnostic assays are allowing clinicians to identify myocardial injury more rapidly, while advanced imaging is improving lesion assessment during PCI. New stent configurations and drug-coated balloons are also widening treatment options for complex anatomy and recurrent coronary disease. Q4. What strategies are companies adopting to strengthen their position in the market? A4. Companies are expanding across different stages of care rather than competing through one product alone. Device manufacturers are targeting complex PCI and recurrent intervention, diagnostic companies are strengthening high-sensitivity testing platforms, and pharmaceutical companies are focusing on antiplatelet therapy and prevention of recurrent cardiovascular events. Q5. What are the most promising applications expected to grow in the industry? A5. Complex and image-guided PCI represents one of the strongest opportunities as hospitals increase use of advanced stents, intravascular imaging and lesion-preparation technologies. Secondary prevention is another important area because patients remain at substantial risk of recurrent cardiovascular events after discharge. Q6. What factors are encouraging adoption across different healthcare settings in the market? A6. Faster diagnostic pathways, established emergency cardiac networks and wider access to catheter-based intervention are supporting adoption. Specialized cardiac centers are also increasing their role in complex PCI and imaging, while hospitals remain essential for the emergency diagnosis and stabilization of acute cases. Sources: ACS Disease Burden and Clinical Management CDC – Heart Disease Facts American Heart Association – 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes European Society of Cardiology – 2023 ESC Guidelines for the Management of Acute Coronary Syndromes Antiplatelet Therapy and Secondary Prevention FDA – BRILINTA (ticagrelor) Prescribing Information FDA – PLAVIX (clopidogrel) Prescribing Information FDA – EFFIENT (prasugrel) Prescribing Information Coronary Intervention and Revascularization FDA – XIENCE Skypoint Everolimus Eluting Coronary Stent System FDA – Resolute Onyx and Onyx Frontier Zotarolimus-Eluting Coronary Stent Systems FDA – AGENT Paclitaxel-Coated Balloon Catheter High-Sensitivity Troponin Diagnostics and Competitive Platforms Roche – Elecsys High-Sensitivity Troponin T Generation 6 Siemens Healthineers – Atellica IM High-Sensitivity Troponin I Assay Table of Contents - Global Acute Coronary Syndrome Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Syndrome Type, Treatment Modality, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Syndrome Type, Treatment Modality, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Syndrome Type, Treatment Modality, and End User Investment Opportunities in the Acute Coronary Syndrome Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Advanced Antiplatelet Therapy, Complex Percutaneous Coronary Intervention, Coronary Imaging, High-Sensitivity Troponin Testing, and Post-ACS Recurrent-Event Prevention Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Acute Coronary Syndrome Diagnosis, Emergency Treatment, Revascularization, and Long-Term Cardiovascular Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Diagnostic Innovation, Reimbursement, Clinical Guidelines, and Healthcare Infrastructure Factors Role of High-Sensitivity Troponin Testing, Emergency PCI Capacity, Drug-Eluting Stents, Coronary Imaging, and Secondary-Prevention Therapies in Market Expansion Clinical Pathway Trends Across Emergency Diagnosis, Revascularization, Hospital Care, and Post-ACS Cardiovascular Management Global Acute Coronary Syndrome Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type: NSTEMI STEMI Unstable Angina Market Analysis by Treatment Modality: Medications Percutaneous Coronary Intervention Coronary Artery Bypass Grafting Market Analysis by End User: Hospitals Cardiac Centers Ambulatory Surgical Centers Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Acute Coronary Syndrome Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Treatment Modality, and End User Country-Level Breakdown: United States Canada Mexico Europe Acute Coronary Syndrome Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Treatment Modality, and End User Country-Level Breakdown: United Kingdom Germany France Italy Spain Netherlands Sweden Norway Rest of Europe Asia Pacific Acute Coronary Syndrome Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Treatment Modality, and End User Country-Level Breakdown: China Japan India South Korea Australia New Zealand Rest of Asia-Pacific Latin America Acute Coronary Syndrome Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Treatment Modality, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Acute Coronary Syndrome Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Syndrome Type, Treatment Modality, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: AstraZeneca Abbott Medtronic Boston Scientific Roche Siemens Healthineers Amgen Sanofi Johnson & Johnson MedTech Terumo Corporation Bayer AG Pfizer Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Antiplatelet Therapy, Coronary Stent Portfolio, Interventional Technology, High-Sensitivity Diagnostic Capability, Laboratory Installed Base, and Regional Presence Clinical Evidence, Regulatory Approval, Reimbursement, and Hospital Procurement Capability Analysis Antiplatelet and Anticoagulant Therapy Positioning Complex PCI, Drug-Eluting Stents, Coronary Imaging, and Lesion-Preparation Competitiveness High-Sensitivity Troponin Diagnostics and Rapid Emergency Department Decision-Support Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Syndrome Type, Treatment Modality, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Clinical, Diagnostic, Reimbursement, and Procurement Risk Analysis Technology Adoption Trends Across Antiplatelet Therapy, Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting, and High-Sensitivity Troponin Testing List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Syndrome Type, Treatment Modality, and End User (2025 vs. 2032) Global Acute Coronary Syndrome Ecosystem and Clinical Care Pathway Analysis